We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 5,261

Crafting Definite Functional Claim Language After MasterMine
  • Baker Botts LLP
  • USA
  • January 8 2018

Section 101 of the Patent Act allows inventors to patent new and useful processes, machines, manufactures, or compositions of matter.1 However, the


Inherent Obviousness Means Element Is Necessarily Present, Not Just Obvious
  • Jones Day
  • USA
  • January 4 2018

In prior blog postings, we have commented on PTAB decisions regarding the standards for demonstrating inherent obviousness


Karnataka High Court rules on entitlement of software industries to concessional rate of power tariff under HT2(A) category
  • Khaitan & Co
  • India
  • January 3 2018

On 27 November 2017, the Karnataka High Court (Court) in Cognizant Technology Solutions India Pvt Ltd v. Bangalore Electricity Supply Company and


Mastermine v. Microsoft: Following Precedent or Pivoting Away?
  • Haynes and Boone LLP
  • USA
  • January 2 2018

At the end of October, in Mastermine Software, Inc. v. Microsoft Corp., No. 2016-2465 (Fed. Cir. Oct. 30, 2017), the Federal Circuit reversed a


What’s patentable about software?
  • DLA Piper
  • USA
  • December 26 2017

If your product or service involves software, you should explore the possibility of filing for and obtaining a software patent


FDA Releases Digital Health Guidance to Spur Innovation
  • Cooley LLP
  • USA
  • December 19 2017

On December 7th, the Food and Drug Administration (FDA) announced the release of a much-anticipated suite of guidance documents that loosen the


Government Review of EHR Incentive Programs Raises Risk of FCA Liability for Health Care and Software Companies
  • Baker McKenzie
  • USA
  • December 18 2017

On 12 December 2017, the Department of Justice announced that, 21st Century Oncology had agreed to pay USD 26 million to the government in part to


340B Update for Hospitals: CMS Publishes FAQs Clarifying Use of Modifiers in Connection with 340B Program Reimbursement Cut on Part B Drugs
  • K&L Gates
  • USA
  • December 18 2017

On December 13, 2017, the Centers for Medicare & Medicaid Services (“CMS”) published subregulatory guidance to answer questions about billing for


When Does Software Become Securities?
  • Sheppard Mullin Richter & Hampton LLP
  • USA
  • December 12 2017

On December 11, 2017, the U.S Securities and Exchange Commission (“SEC”) issued a cease and desist order (“Order”) against Munchee, Inc.’s (“Munchee”


Connected Devices and the Right-To-Repair Movement
  • Baker Botts LLP
  • USA
  • December 7 2017

The market for consumer devices connected to the internet has ballooned in recent years, and many household products, ranging from washing machines to